Serial Ultrasound to Detect Early Response to Immunotherapy in Metastatic RCC
连续超声检测转移性肾细胞癌免疫治疗的早期反应
基本信息
- 批准号:10357118
- 负责人:
- 金额:$ 18.09万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-03-09 至 2024-02-29
- 项目状态:已结题
- 来源:
- 关键词:AngiopoietinsAutoantibodiesAutoimmune HepatitisBiological MarkersBloodBlood VesselsBlood flowCTLA4 geneCaliberClinicClinic VisitsClinicalContrast MediaDetectionDoppler UltrasoundEarly treatmentEnrollmentErythrocytesExcisionExposure toFatigueHashimoto DiseaseHepatitisImageImaging TechniquesImmune checkpoint inhibitorImmune systemImmunotherapyIndividualIodineIonizing radiationKidneyMalignant NeoplasmsMeasurementMeasuresMetastatic Renal Cell CancerMetastatic toModalityMorphologic artifactsMotionNivolumabNoiseOncologyPatientsPerfusionPharmaceutical PreparationsPilot ProjectsPorosityPrimary LesionPulmonary InflammationRadiology SpecialtyRenal Cell CarcinomaRenal carcinomaResistanceScanningSignal TransductionT-LymphocyteThyroiditisTimeTreatment Side EffectsTumor BurdenTumor Suppressor ProteinsUltrasonographyVisitX-Ray Computed Tomographyangiogenesisanti-CTLA4anti-PD-1basecancer therapycheckpoint inhibitioncheckpoint therapycontrast enhancedeffective therapyineffective therapiesinnovationipilimumabkidney dysfunctionnanobubblenephrotoxicitypredicting responsepreventquantitative imagingrapid detectionresponseside effectstandard measurestandard of caretreatment responsetumorultrasound
项目摘要
Project Summary
We propose a pilot study to detect response to immunotherapy as early as 3 weeks after initiating
therapy, using Doppler ultrasound and contrast-enhanced ultrasound (CEUS) to measure changes in
tumor vascularity in patients with metastatic renal cell carcinoma (mRCC). Biomarkers to rapidly detect
response to RCC therapy are urgently needed, because not all patients respond to first-line treatment with
combined CTLA-4 immune checkpoint inhibitor (ipilimumab) plus anti-PD-1 immune checkpoint inhibitor
(nivolumab). Yet, all patients endure the side effects of this combination treatment (fatigue, autoimmune
hepatitis/thyroiditis/pneumonitis etc.) while awaiting standard-of-care computed tomography (CT) imaging.
Currently, 12 weeks is required to assess response by measuring decreases in tumor diameters with CT because
tumor size does not significantly change before 12 weeks of therapy. Rapid detection of response to RCC therapy
would minimize use of ineffective drugs and allow patients to discontinue ineffective therapies and continue only
effective therapy. We have found that imaging-based measurements of tumor vascularity, such as perfusion CT
scans, can detect early response to therapy in mRCC. But these require potentially nephrotoxic iodine contrast
agents and visits to the radiology department. We have developed highly sensitive, non-contrast, vascular
imaging using advanced power Doppler ultrasound that can be performed at bedside in the oncology clinic to
image vessels as small as 1 mm in diameter. Now, we propose to use advanced power Doppler ultrasound for
a pilot study to assess changes in tumor vascularity, during routine oncology clinic visits for patients receiving
combined therapy, and compare it to conventional power Doppler and contrast-enhanced ultrasound (CEUS,
using non-nephrotoxic micro-/nanobubble contrast agents). We hypothesize that changes in tumor
vascularity, measured by ultrasound, can detect response to treatment earlier than changes in tumor
diameters. We will enroll 30 patients with mRCC, to be evaluated with Doppler ultrasound and CEUS before
treatment and after 3 weeks and 6 weeks of combined ipilimumab and nivolumab therapy. Our pilot study aims
to determine if 1) Doppler ultrasound and/or CEUS can detect changes as early as 3 and/or 6 weeks after
initiating immunotherapy; 2) if changes detected by ultrasound correlate with response measured by standard-
of-care CT scan after 12 weeks of therapy; and 3) which ultrasound time point (3 weeks or 6 weeks) better
anticipates 12-week results. We will use ultrasound imaging to accelerate detection of response to
combined ipilimumab + nivolumab. If successful, we can apply our approach to additional tumors and drugs,
as changes in tumor vascularity are a key mechanism of response to most cancer therapies.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jeremy Dahl其他文献
Jeremy Dahl的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jeremy Dahl', 18)}}的其他基金
B7-H3 Targeted Ultrasound Molecular Imaging System for Early Breast Cancer and Metastatic Detection
B7-H3 用于早期乳腺癌和转移检测的靶向超声分子成像系统
- 批准号:
10584161 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Serial Ultrasound to Detect Early Response to Immunotherapy in Metastatic RCC
连续超声检测转移性肾细胞癌免疫治疗的早期反应
- 批准号:
10589070 - 财政年份:2022
- 资助金额:
$ 18.09万 - 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
- 批准号:
10410471 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
- 批准号:
9885175 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Early therapeutic monitoring of response to therapy with serial ultrasound in metastatic RCC
转移性肾细胞癌连续超声治疗反应的早期治疗监测
- 批准号:
10046819 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Improving Liver Ultrasound Image Quality in Difficult-to-Image Patients
提高难以成像患者的肝脏超声图像质量
- 批准号:
10634660 - 财政年份:2020
- 资助金额:
$ 18.09万 - 项目类别:
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug Delivery
使用超声引导药物输送对肝细胞癌进行治疗性 miRNA 调节
- 批准号:
9299022 - 财政年份:2017
- 资助金额:
$ 18.09万 - 项目类别:
Therapeutic miRNA Modulation of Hepatocellular Carcinoma Using Ultrasound Guided Drug Delivery
使用超声引导药物输送对肝细胞癌进行治疗性 miRNA 调节
- 批准号:
9893823 - 财政年份:2017
- 资助金额:
$ 18.09万 - 项目类别:
High Sensitivity Molecular Ultrasound Imaging in Pancreatic Cancer
胰腺癌的高灵敏度分子超声成像
- 批准号:
9302759 - 财政年份:2016
- 资助金额:
$ 18.09万 - 项目类别:
High Sensitivity Flow Imaging of the Human Placenta with Coherence-Based Doppler Ultrasound
使用相干多普勒超声对人胎盘进行高灵敏度血流成像
- 批准号:
9270591 - 财政年份:2015
- 资助金额:
$ 18.09万 - 项目类别:
相似海外基金
Defining the cellular origin of pathogenic autoantibodies
定义致病性自身抗体的细胞起源
- 批准号:
EP/Y031091/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Fellowship
Do autoantibodies to aberrantly glycosylated MUC1 drive extra-articular rheumatoid arthritis, and can GSK assets prevent driver antigen formation?
针对异常糖基化 MUC1 的自身抗体是否会导致关节外类风湿性关节炎,GSK 资产能否阻止驱动抗原形成?
- 批准号:
MR/Y022947/1 - 财政年份:2024
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
Autoantibodies and antibody-secreting cells in neurological autoimmune diseases: from biology to therapy
神经性自身免疫性疾病中的自身抗体和抗体分泌细胞:从生物学到治疗
- 批准号:
479128 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Operating Grants
Autoantibodies to tumor-derived neoepitopes as biomarkers and immunoPET agents for the early detection of small cell lung cancer
肿瘤衍生新表位的自身抗体作为生物标志物和免疫 PET 试剂用于小细胞肺癌的早期检测
- 批准号:
10715807 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Role of pharmacological activity of autoantibodies in ME/CFS
自身抗体药理活性在 ME/CFS 中的作用
- 批准号:
MR/Y003667/1 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Research Grant
Pathological Mechanisms of Immune-Mediated Cerebellar Ataxia with Associated Sez6L2 Autoantibodies
免疫介导的小脑共济失调与相关 Sez6L2 自身抗体的病理机制
- 批准号:
10740682 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Pathogenesis of idiopathic nephrotic syndrome: defining the role of B cells and autoantibodies reactive to podocyte proteins
特发性肾病综合征的发病机制:定义 B 细胞和足细胞蛋白反应性自身抗体的作用
- 批准号:
487849 - 财政年份:2023
- 资助金额:
$ 18.09万 - 项目类别:
Operating Grants
Analysis of pathogenesis associated with mutation of complement associated gene and autoantibodies in development/progression of C3 nephropathy.
补体相关基因突变和自身抗体在C3肾病发生/进展中的发病机制分析。
- 批准号:
22K08309 - 财政年份:2022
- 资助金额:
$ 18.09万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Depleting autoantibodies for the treatment of autoimmunity
消耗自身抗体来治疗自身免疫
- 批准号:
10481071 - 财政年份:2022
- 资助金额:
$ 18.09万 - 项目类别:














{{item.name}}会员




